ESPE-ESE 2025 10 - 13 May 2025

Efficacy and safety of somapacitan versus daily growth hormone at 52 weeks in patients with growth hormone deficiency: pooled analysis of the randomised REAL 3, REAL 4 and REAL 6 clinical trials

Authors :

Lars Sävendahl¹; Aristides Maniatis²; Martin Wabitsch³; Alberto Pietropoli⁴; Nicky Kelepouris⁵; Michael Højby⁶; Junfen Fu⁷; Jun Mori⁸; Bradley S. Miller⁹

Affiliations

View Details Hide Details

Keywords

Rare Endocrine Disorder

Congress poster

Somapacitan

Search Science Hub

Are you a healthcare professional?

Efficacy and safety of somapacitan versus daily growth hormone at 52 weeks in patients with growth hormone deficiency: pooled analysis of the randomised REAL 3, REAL 4 and REAL 6 clinical trials